Company Hypera S.A.

HYPE3

BRHYPEACNOR0

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Ratings for Hypera S.A.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Sao Paulo Other stock markets 04:07:00 2024-04-24 pm EDT			5-day change	1st Jan Change
28.78 ^BRL	-1.07%		+1.70%	-19.50%

Mar. 14	Transcript : Hypera S.A., Q4 2023 Earnings Call, Mar 14, 2024
Mar. 14	Hypera S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Hypera (formerly Hypermarcas) is the Brazilian leader in the manufacture and marketing of pharmaceutical products. The products are sold primarily under the Addera D3, Adocyl, AdultMax, Alivium, Apracur, Atroveran, Benegrip, Bigfral, Biotonico Fontoura, Coristina, Cremer, Doril, Engov, Epocler, Lisador and Neo Quimica. The activity is organized around 3 families of products :

- OTC medicines;

- prescription medicines;

- branded generic medicines.

Number of employees: 10,301

BRL in Million	2022	Weight	2023	Weight	Delta
Medical and Cosmetics Products 100.0 %	7,546	100.0 %	7,915	100.0 %	+4.88%

BRL in Million	2022	Weight	2023	Weight	Delta
Brazil 100.0 %	7,546	100.0 %	7,915	100.0 %	+4.88%

Managers	Title	Age	Since
Ramon Sanches Frutuoso Silva DFI	Director of Finance/CFO	36	22-02-23
Juliana Aguinaga Damião Salem CMP	Compliance Officer	40	07-12-31
Adalmario Ghovatto Satheler do Couto IRC	Investor Relations Contact	42	15-12-31
Luiz Eduardo Sales Clavis SAM	Sales & Marketing	52	11-12-31
Vivian Karina Trujillo Angiolucci PRN	Corporate Officer/Principal	43	13-03-31
Armando Luis Ferreira AUD	Comptroller/Controller/Auditor	69	08-12-31

Members of the board	Title	Age	Since
Esteban Malpica Fomperosa BRD	Director/Board Member	74	-
Bernardo Malpica Hernández BRD	Director/Board Member	58	-
Luciana C. Fleischner Alves de Queiroz BRD	Director/Board Member	49	-
Álvaro Stainfeld Link CHM	Chairman	53	14-04-16
Maria Carolina Ferreira Lacerda BRD	Director/Board Member	51	16-12-31
Hugo Barreto Sodré Leal BRD	Director/Board Member	48	18-12-31
Flair José Carrilho BRD	Director/Board Member	76	18-12-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	633,166,794	370,448,706 ( 58.51 %)	512,303 ( 0.0809 %)	58.51 %

Name	Equities	%	Valuation
João Alves de Queiroz Filho 21.38 %	135,426,898	21.38 %	891 M R$
Maiorem SA de CV 14.74 %	93,371,780	14.74 %	614 M R$
Capital Research & Management Co. (International Investors) 10.40 %	65,867,004	10.40 %	433 M R$
MFS International (UK) Ltd. 1.257 %	7,962,470	1.257 %	52 M R$
UBS Asset Management (Singapore) Ltd. 1.196 %	7,578,241	1.196 %	50 M R$
Swedbank Robur Fonder AB 0.6013 %	3,808,573	0.6013 %	25 M R$
Itaú Unibanco SA 0.5461 %	3,459,004	0.5461 %	23 M R$
Una Capital Ltda. 0.3773 %	2,390,175	0.3773 %	16 M R$
BB Gestão de Recursos DTVM SA 0.2819 %	1,785,324	0.2819 %	12 M R$
Morgan Stanley Administradora de Carteiras SA 0.2359 %	1,494,148	0.2359 %	10 M R$

Name	Equities	%	Valuation
HOPPE & SCHULTZ AG 0.002210 %	14,000	0.002210 %	92 414 R$
Irish Life Investment Managers Ltd. 0.000489 %	3,100	0.000489 %	20 463 R$

Name	Equities	%	Valuation
HYPERA S.A. 0.22%	1,422,171	0.22%	9,356,036 $

Hypera SA

Avenida Magalhães de Castro, 4800 Edifício Continental Tower

05676-120, São Paulo

+55 11 3627 4206

http://www.hyperapharma.com.br

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

28.78 BRL

Average target price

42.28 BRL

Spread / Average Target

+46.92%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
HYPERA S.A.	-19.50%	3.53B
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+22.91%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ASTRAZENECA PLC	+13.04%	219B
ROCHE HOLDING AG	-9.57%	196B
NOVARTIS AG	+6.35%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals